A photoacoustic imaging-guided thermosensitive liposome with enhanced mild photothermal properties and its application

Temperature-sensitive liposomes were prepared by modifying glucose oxidase on gold nanorods and combining hypoxic activation prodrugs and YAP small molecule inhibitors, which solved the tumor heat resistance and hypoxic environment in mild photothermal therapy. The problem has achieved precise targeting and efficient killing of tumor cells, and improved the therapeutic effect.

CN118304263BActive Publication Date: 2024-11-19SHANDONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410470373.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-18
Publication Date
2024-11-19
Estimated Expiration
2044-04-18

AI Technical Summary

Technical Problem

When mild photothermal therapy ablates tumors at low temperatures, rapid expression of heat shock proteins leads to tumor cells' heat resistance, the therapeutic effect of existing HSP inhibitors is delayed, and tumor microenvironment hypoxic environment resistance treatment.

Method used

By modifying glucose oxidase on the gold nanorod, combining hypoxic activation prodrugs and YAP small molecule inhibitors, temperature-sensitive liposomes are prepared, and near-infrared lasers are used to guide the drug to controllable release at the tumor site, inhibiting ATP production and Tumor dryness enhances the efficiency of mild photothermal therapy.

Benefits of technology

It achieves precise targeting and effective killing of tumor cells, improves the therapeutic effect of mild photothermal therapy, and enhances the sensitivity and therapeutic effect to tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118304263B_ABST
    Figure CN118304263B_ABST
Patent Text Reader

Abstract

A thermosensitive liposome VTGA-ML, the liposome comprising a blank liposome and an active substance, a YAP small molecule inhibitor VP, a hypoxia-activated prodrug TH-302, and a glucose oxidase-modified gold nanorod GA. After intravenous injection, VTGA-ML actively targets and accumulates at the tumor site under the mediation of α-MSH. After near-infrared laser irradiation, VP, TH-302, and GA achieve temperature-sensitive controllable release. GA consumes glucose and oxygen, inhibits ATP production, inhibits HSP expression from the source, enhances the mPTT effect and the hypoxia level of TME. Then, TH-302 and VP jointly utilize the hypoxic environment and effectively regulate the stemness of tumor cells, ultimately achieving mPTT enhancement and improving the effect of tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of pharmaceutical preparations, and in particular to a photoacoustic imaging-guided thermosensitive liposome and an application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Mild photothermal therapy (mPTT) is a method that ablates tumors within a low temperature range (38-43°C) and avoids damage to normal cells. However, tumor cell damage caused by mild heat can easily lead to a rapid increase in the expression of heat shock protein (HSP). The upregulated HSP can repair heat-damaged cells and cause tumor cells to develop heat resistance, which cannot completely eradicate the tumor.

[0004] At present, some HSP inhibitors, such as gambogic acid, tanespimycin (17-AAG), ganetespib (STA-9090), etc., have been used to improve the efficiency of mPTT. Unfortunately, these HSP inhibitors can only inhibit the activity of HSP after heat stimulation, resulting in delayed therapeutic effect. The expression of HSP is closely related to the concentration level of adenosine triphosphate (ATP). Introducing a potent glucose consumer is an effective method to reduce the ATP level in tumors. Among them, glucose oxidase (GOx) is an endogenous oxidoreductase widely present in organisms, with good biocompatibility and low toxicity. It can effectively inhibit the production of intracellular ATP, thereby inhibiting the expression of HSP, overcoming tumor heat resistance, and improving the efficiency of mPTT. Therefore, inhibiting the production of HSP from the source is an effective method to improve the efficacy of mPTT.

[0005] Tumor cells rely on the intake of nutrients and oxygen from the tumor microenvironment (TME) to promote their own growth and progression. The hypoxic environment of the TME promotes tumor cell DNA repair, enhances tumor cell stemness, induces cell self-renewal and enrichment, and resists the therapeutic effect of mPTT. Evofosfamide (TH-302) is a hypoxia-activated prodrug that can be activated under hypoxic conditions and attack tumor tissues that lack oxygen supply. The YAP small molecule inhibitor Verteporfin (VP) can block the pairing of the transcription regulator YAP with the transcription factor family TEAD, reduce tumor stem cell-like characteristics, and increase the sensitivity of tumor tissue to chemotherapeutic drugs. Therefore, by combining the hypoxic environment of the tumor and effectively regulating the stemness of tumor cells, mPTT synergy can be achieved and the therapeutic effect of the tumor can be improved. Summary of the invention

[0006] The purpose of the present invention is to improve the effect of mPTT by inhibiting the production of HSP from the source, and at the same time, through a drug combination, jointly utilize the hypoxic environment of the tumor and effectively regulate the stemness of tumor cells to achieve mPTT enhancement and improve the therapeutic effect of the tumor.

[0007] Gold nanorods (AuNRs) have good photothermal conversion performance and are effective PTT photothermal converters. In order to achieve spatial consistency between the effects of mPTT and GOx, the present invention chemically modifies GOx on the surface of AuNRs to obtain glucose oxidase-modified gold nanorods (GA). In addition, considering that cetyltrimethylammonium bromide (CTAB) is still attached to the surface of GA after modification, it may have strong toxicity. Therefore, in order to shield the charge, improve biocompatibility and achieve precise and controllable release of drugs, the temperature-sensitive lipid material dipalmitoylphosphatidylcholine (DPPC) is selected as the main carrier component, and the targeting factor distearoylphosphatidylethanolamine-polyethylene glycol 2000-α-melanocyte stimulating hormone (DSPE-PEG) is modified on the surface. 2000 -α-MSH), and GA was encapsulated to prepare liposomes, which were named GA-ML.

[0008] Then, the YAP small molecule inhibitor VP and the hypoxia activated prodrug TH-302 were co-loaded in the phospholipid bilayer of the thermosensitive liposome GA-ML, and DSPE-PEG was carefully constructed. 2000-α-MSH-modified thermosensitive liposomes loaded with VP, TH-302 and GA are named VTGA-ML. After intravenous injection, VTGA-ML actively targets and accumulates at the tumor site under the mediation of α-MSH. After near-infrared laser irradiation, VP, TH-302 and GA achieve temperature-sensitive controllable release. GA consumes glucose and oxygen, inhibits ATP production, inhibits HSP expression from the source, enhances the mPTT effect and the hypoxia level of TME. TH-302 and VP jointly utilize the hypoxic environment and effectively regulate the stemness of tumor cells, ultimately achieving mPTT enhancement and improving the effect of tumor treatment.

[0009] In a first aspect, the present invention provides a liposome, wherein the liposome comprises a blank liposome and active substances TH-302, VP and GA;

[0010] Furthermore, the mass ratio of the active ingredients TH-302, VP and GA in the liposome is 10:1:3;

[0011] Furthermore, a method for preparing liposomes is provided, wherein the specific steps are: preparing liposomes by thin film dispersion method; DPPC, cholesterol, TH-302, VP, distearoylphosphatidylethanolamine-polyethylene glycol 2000-α-melanocyte stimulating hormone (DSPE-PEG 2000 -α-MSH) was dissolved in a certain volume of methanol solution, placed in a 25 mL pear-shaped bottle, and after rotating at 40°C to form a film, the above-mentioned GA solution was added, and ultrasonic hydration was performed at 45°C for 10 min to obtain a stable thermosensitive liposome (VTGA-ML) solution;

[0012] Furthermore, an optimized formula for preparing liposomes is provided, specifically, the DPPC concentration is 10 mg / mL, the DPPC / cholesterol mass is 8:1, the TH-302:DPPC mass is 1:10, and the hydration temperature is 45°C;

[0013] Furthermore, the preparation method of GA in the liposome is:

[0014] (1) Thiol-polyethylene glycol 2000-amino (SH-PEG 2000 -NH2) was modified on the surface of AuNRs by ultrasound and stirring to obtain gold nanorod-polyethylene glycol 2000-amino (AuNR-PEG 2000 -NH2).

[0015] (2) Glucose oxidase, under the catalysis of EDC and NHS, reacts with AuNRs-PEG through the carboxyl group of glucose oxidase 2000 The amino groups of -NH2 undergo amide reaction to form GA.

[0016] In one aspect, the present invention provides a drug combination, wherein the drug combination is TH-302 and VP;

[0017] Furthermore, an optimal synergistic ratio of two drugs, TH-302 and VP, is provided, wherein the optimal synergistic molar ratio of the drug combination is 10:1, and has an obvious synergistic effect;

[0018] Another aspect of the present invention provides an application of a drug combination TH-302 in combination with VP in anti-tumor drugs.

[0019] In another aspect, the present invention provides a use of liposomes in photoacoustic imaging;

[0020] Another aspect of the present invention provides a use of a liposome in the preparation of a mild photothermal therapy drug.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] (1) TH-302 can be activated under hypoxic conditions and attack tumor tissues that lack oxygen supply. VP can block the pairing of the transcription regulator YAP with the transcription factor family TEAD, reduce tumor stem cell-like characteristics, and increase the sensitivity of tumor tissues to chemotherapeutic drugs. The combination of VP and TH-302 can jointly utilize the hypoxic environment and effectively regulate the stemness of tumor cells, ultimately achieving mPTT synergy and improving the effect of tumor treatment.

[0023] (2) After intravenous injection, VTGA-ML actively targets the tumor site and accumulates under the mediation of α-MSH. After near-infrared laser irradiation, VP, TH-302 and GA achieve temperature-sensitive controllable release. GA consumes glucose and oxygen, inhibits ATP production, inhibits HSP expression from the source, enhances the mPTT effect and the hypoxia level of TME. TH-302 and VP jointly utilize the hypoxic environment and effectively regulate the stemness of tumor cells, ultimately achieving mPTT synergy and improving the effect of tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0025] Figure 1 : Cell viability of TH-302 / VP mixtures with different molar ratios in B16F10 cells (n=3);

[0026] Figure 2 :Single factor investigation results (a) Investigation of liposome drug loading and encapsulation efficiency at different phospholipid concentrations (b) cholesterol / phospholipid ratios (c) drug-lipid ratios (d) temperatures;

[0027] Figure 3 :Preparation and characterization of VTGA (a) Zeta potential and TEM image of VTGA-ML (b) Storage stability of VTGA-ML at 4°C for 15 days (n=3);

[0028] Figure 4 : (a) VP and (b) TH-302 release curves from VTGA-ML within 48 h (n=3) (***p<0.001);

[0029] Figure 5 : VTGA-ML uptake in B16F10 cells (a) fluorescence photos and (b) flow cytometry uptake analysis (n=3, scale bar 200 μm) (**p<0.01);

[0030] Figure 6 :(a) VTGA-ML solution at 0.33W / cm 2 Infrared thermal image under power (b) temperature change and (c) photothermal stability curve;

[0031] Figure 7 :(a)0.33W / cm 2 Infrared thermal image and (b) temperature curve of the tumor within 5 min under laser irradiation (n=3);

[0032] Figure 8 :(a) VTGA-ML in vitro photoacoustic imaging photos and (b) PA average intensity data analysis;

[0033] Fig. 9 :(a) PAI images of C57BL / 6 tumor-bearing mice at different time points and (b) average PA intensity values ​​(n=3) (***p<0.001);

[0034] Fig.10 : Cytotoxicity of different preparations on B16F10 cells (n=3). DETAILED DESCRIPTION

[0035] It should be noted that the following detailed descriptions are all illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0036] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0037] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in combination with specific embodiments and comparative examples.

[0038] Example 1. Preparation of GA-loaded targeted thermosensitive liposomes (VTGA-ML)

[0039] 1.1 Investigation of synergistic effect between TH-302 and VP

[0040] Different drug combination ratios will produce different synergistic therapeutic effects. The cytotoxicity of TH-302 / VP on B16F10 cells at different combination ratios was investigated by in vitro cytotoxicity experiments. TH-302 and VP concentrated stock solutions of certain concentrations were prepared respectively, and the two concentrated stock solutions were mixed at different molar ratios, so that the molar ratios of TH-302:VP were 25:1, 20:1, 15:1, 10:1, and 5:1, respectively, to obtain five TH-302 / VP mixed solutions with different molar ratios. The drugs were diluted with culture medium and added to a 96-well plate containing B16F10 cells, so that the final concentration of the drug TH-302 ranged from 2.2 to 220 μM, and the VP concentration could be calculated according to the molar ratio of the two drugs. A total of 5 replicate wells were set at each concentration, and the experiment was repeated 3 times. After incubation for 48 hours with the drug, 5 mg / mL MTT reagent (20 μL) was added to each well and incubated for another 4 hours. Finally, after discarding the supernatant, 200 μL DMSO was added to each well and the absorbance was measured at 570 nm using an ELISA reader. All samples were performed in triplicate and the data were expressed as mean ± SD (n = 3). The cell viability was calculated based on the results using the following formula:

[0041]

[0042] After calculating the cell inhibition rate based on the measured absorbance values, GraphPad Prism software was used to analyze the half inhibitory concentration (IC 50 ) is calculated. According to IC 50 The synergy index of TH-302 / VP at different molar ratios was calculated by the following formula:

[0043]

[0044] Among them, D1 and D2 represent the drug concentrations required to inhibit half of the cell growth when drug 1 and drug 2 are used in combination. m1 and D m2 It represents the drug concentration required to inhibit half of the cell growth when each drug is administered alone. CI values ​​greater than, equal to, and less than 1 represent antagonistic, additive, and synergistic effects, respectively.

[0045] Cell survival rate of single TH-302 and the combination of two drugs is as follows Figure 1 As shown in the figure, compared with single drugs, the cell survival rate of the combination group at any concentration was lower, indicating that the combination of the two drugs can enhance the killing effect on tumor cells, and therefore has a high potential for combination. Based on the results of cell survival rate, the IC 50 The results of the synergy index (CI) are shown in Table 1.

[0046] Table 1 IC at different ratios of TH-302 and VP 50 and synergy index CI

[0047]

[0048]

[0049] From Table 1, the IC of single TH-302 and VP is 50 The values ​​are IC 50 =48.33±2.88μM, IC 50 =8.93±0.16μM, while the IC 50 The value is significantly lower than that of a single drug. At the combination ratio of 10:1 and 5:1, the CI value of the combination of the two drugs is less than 1, proving that the combination of the two drugs has a high synergistic effect. Among them, when the combination ratio is 10:1, the CI value is the lowest, which is 0.85, indicating that the two drugs can produce the best synergistic effect at this ratio. Therefore, 10:1 is selected as the optimized ratio of the two drugs for the preparation of subsequent liposome preparations.

[0050] 1.2 Preparation of VTGA-ML

[0051] Liposomes were prepared by thin film dispersion method. DPPC, cholesterol, TH-302, VP, DSPE-PEG 2000 -α-MSH was dissolved in a certain volume of methanol solution, placed in a 25 mL pear-shaped bottle, and rotated at 40°C to form a film. The above-mentioned GA solution was added and ultrasonically hydrated at 45°C for 10 minutes to obtain a stable liposome solution (VTGA-ML).

[0052] Example 2: Optimization of formulation for preparation of VTGA-ML liposomes

[0053] In order to screen the best formulation process for preparing VTGA-ML, the drug loading (EE%) and encapsulation efficiency (DL%) of TH-302 were used as indicators to investigate the single factors of phospholipid concentration (5-15 mg / ml), phospholipid to cholesterol ratio (4-12:1), drug-lipid ratio (1:8-12) and ultrasonic hydration temperature (40-50°C). The drug loading (DL%) and encapsulation efficiency (EE%) were calculated according to formula (1) and (2).

[0054] Prescription 1: 10mg DPPC, 1.25mg cholesterol, 1mg TH-302, 1.01mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 45°C for 10 min.

[0055] Prescription 2: 20mg DPPC, 2.5mg cholesterol, 2mg TH-302, 2.02mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 45°C for 10 min.

[0056] Prescription 3: 30mg DPPC, 3.75mg cholesterol, 3mg TH-302, 3.03mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 45°C for 10 min.

[0057] Prescription 4: 20mg DPPC, 5mg cholesterol, 2mg TH-302, 2.41mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 45°C for 10 min.

[0058] Prescription 5: 20mg DPPC, 1.67mg cholesterol, 2mg TH-302, 1.89mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 45°C for 10 min.

[0059] Prescription 6: 20mg DPPC, 2.5mg cholesterol, 2.5mg TH-302, 2.02mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 45°C for 10 min.

[0060] Prescription 7: 20 mg DPPC, 2.5 mg cholesterol, 1.67 mg TH-302, 2.02 mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 45°C for 10 min.

[0061] Prescription 8: 20mg DPPC, 2.5mg cholesterol, 2.0mg TH-302, 2.02mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 40°C for 10 min.

[0062] Prescription 9: 20mg DPPC, 2.5mg cholesterol, 2.0mg TH-302, 2.02mg DSPE-PEG 2000 -α-MSH was dissolved in 2 mL of methanol solution and placed in a 25 mL pear-shaped bottle. After rotating at 40°C to form a film, 2 mL of the above GA solution was added and hydrated under ultrasound at 50°C for 10 min.

[0063]

[0064]

[0065] Where W loaded drug and W lipids Represent drug content and total phospholipid content respectively. total drug Represents the total dose.

[0066] like Figure 2 a. With the increase of phospholipid concentration, the EE% and DL% of TH-302 first increased and then decreased. When the phospholipid concentration was 10 mg / ml, the EE% and DL% were the largest. Figure 2 b. As the ratio of phospholipids to cholesterol increases, the EE% and DL% of TH-302 first increase and then decrease. When the ratio of phospholipids to cholesterol is 8:1, the EE% and DL% are the largest. Figure 2c. As the drug-lipid ratio decreases, the EE% and DL% of TH-302 first increase and then decrease. When the drug-lipid ratio is 1:10, the EE% and DL% are the largest. Figure 2 d. As the temperature increases, the EE% and DL% of TH-302 increase. Considering that too high a temperature will affect the enzyme activity of GOx, 45°C is selected as the hydration temperature. Therefore, the phospholipid concentration of 10 mg / mL, phospholipid / cholesterol of 8:1, drug-lipid ratio of 1:10, and hydration temperature of 45°C were finally selected as the optimal process prescription for VTGA-ML.

[0067] Example 3: Investigation of VTGA-ML physical and chemical properties

[0068] The Zeta potential of VTGA-ML was measured by dynamic light scattering analyzer, and its morphology was observed by transmission electron microscopy. Figure 3 a, the potential of VTGA-ML is 1.85±0.33mV, and the morphology is uniform. At the same time, the drug loading and encapsulation efficiency of VTGA-ML were investigated for three batches of stability, as shown in Table 2.

[0069] Table 2 Reproducibility results of three batches of VTGA-ML drug loading (DL%) and encapsulation efficiency (EE%) (n=3)

[0070]

[0071] As shown in Table 2, the drug loading and encapsulation efficiency of three batches were reproducible and stable, meeting the experimental requirements.

[0072] Example 4: VTGA-ML stability study

[0073] To further investigate the stability of VTGA-ML, the prepared VTGA-ML was evaluated at 4°C, and the Zeta potential of VTGA-ML was recorded every 2 days for a total of 15 days to evaluate the storage stability of VTGA-ML. Figure 3 As shown in b, the potential of VTGA-ML did not change significantly within 15 days, and no aggregation or precipitation was observed.

[0074] Example 5: Investigation of in vitro release ability of VTGA-ML

[0075] The dialysis bag method was used to determine the influence of VTGA-ML on the light condition (0.33 W / cm 2 , 808 nm, 5 min) release curves of VP and TH-302. 1.0 mL of free VP, TH-302 and VTGA-ML solution was added to the dialysis bag, which was then placed in a tube containing 10 mL of PBS (pH 7.4, containing 1% Tween 80) and shaken at 100 rpm at 37°C. The laser group used 808 nm near-infrared laser at 0.33 W / cm2 Irradiate for 5 min. Replace the release medium with 10 mL of fresh medium at the predetermined time point and collect the samples. Determine the concentrations of VP and TH-302 released by them by UV spectrophotometry and HPLC, respectively. Each group was carried out in parallel 3 times.

[0076] The rupture of VTGA-ML can promote the release of drugs. Figure 4 As shown in ab, the free drug and free drug plus laser (VP and VP+L; TH-302 and TH-302+L) groups showed similar cumulative release, indicating that laser had no significant effect on free drug release. In addition, the VP and TH-302 release amounts in the VTGA-ML+laser (VTGA-ML+L) group were 68.09±1.39% and 73.11±0.23%, respectively, which were significantly higher than those in the VTGA-ML group (p<0.001, p<0.001). These results indicate that 808nm laser irradiation can promote the cumulative release of VP and TH-302.

[0077] Example 6: In vitro cellular uptake

[0078] In order to investigate the active targeting of the preparation, B16F10 cells were selected for the experiment. The hydrophobic drug coumarin 6 (C6) was selected as a tracer to prepare C6-GA-L and C6-GA-ML. B16F10 cells (1×10 5 Cells / well) were inoculated in a 12-well plate and incubated overnight. The next day, fresh culture medium containing free C6, C6-GA-L and C6-GA-ML was added to the corresponding wells and incubated for 0.5h and 2h respectively. The culture medium was then discarded and the cells were washed 3 times with PBS. They were stained with Hoechst 33342 for 15min. Finally, the cells were washed 2 times with PBS and imaged using a fluorescence microscope. B16F10 cells incubated with different preparations were digested and collected with trypsin and analyzed by flow cytometry after washing with PBS.

[0079] As shown in the fluorescence microscopy images ( Figure 5 a) and flow cytometry analysis ( Figure 5 As shown in b), at 0.5h and 2h, the uptake rate of C6-GA-ML by B16F10 was significantly higher than that of C6-GA-L (p<0.01, p<0.01). After B16F10 was pretreated with free α-MSH, the cellular uptake of C6-GA-ML was inhibited. These results indicate that modification by α-MSH can mediate the active targeting of VTGA-ML.

[0080] Example 7: Investigation of in vitro mild photothermal (mPTT) performance of VTGA-ML

[0081] In order to obtain the ideal mPTT effect, the photothermal performance of VTGA-ML was investigated, and the heating curves of VTGA-ML and GA-ML were compared. At the predetermined time, photos were taken with an infrared thermal imager and the temperature was recorded with a digital thermometer.

[0082] like Figure 6 a and 6b, at 0.33W / cm 2 At the power of 1.5, the in vitro infrared thermal image and temperature heating effect of VTGA-ML (concentration of 300 μg / mL) were similar to those of GA-ML, rising by 7.8°C ( Figure 6 b) The results show that after GA-ML was loaded with VP and TH-302, the mPTT temperature-raising effect was not affected, which met the formulation requirements. In addition, after four heating and cooling cycles, the temperature was recorded at the predetermined time. The results are as follows Figure 6 As shown in c, the photothermal temperature curve remains almost unchanged, showing excellent photostability and thermal stability.

[0083] Example 8: Investigation of the in vivo mild photothermal performance of VTGA-ML

[0084] In order to investigate the mPTT performance of VTGA-ML in vivo, female B16F10 tumor-bearing mice were used as model animals. The photothermal conversion efficiency of VTGA-ML in vivo was evaluated 12 h after administration. At this time, VTGA-ML had good tumor accumulation. Mice were intravenously injected with NS, GA-ML, and VTGA-ML. After 12 h of administration, the mice were anesthetized and the power was 0.33 W / cm 2 The mice were irradiated with near-infrared laser (808 nm). During the irradiation process, the mice were photographed at predetermined time points using an infrared thermal imager. All samples were prepared in triplicate and the data are presented as mean ± SD.

[0085] Infrared thermal imaging ( Figure 7 a) shows that as the laser irradiation time increases, the temperature of the tumor site in each group gradually increases, and the temperature in the VTGA-ML group is slightly higher than that in the GA-ML group. Infrared thermal imaging temperature curve ( Figure 7 b) shows that at 0.33W / cm 2 At a power of 1.5, the local tissue temperature of the VTGA-ML group increased to about 42.6°C within 5 minutes, slightly higher than that of the GA-ML group, which met the temperature requirements of mPTT. These results show that VTGA-ML can effectively improve the photothermal conversion efficiency of local mPTT in tumors.

[0086] Example 9: Performance evaluation of in vitro photoacoustic imaging (PAI) of VTGA-ML

[0087] VTGA-ML also contains AuNRs, a nano-gold material, which can be used as a photoacoustic effector for photoacoustic imaging (PAI). We measured the intensity of the photoacoustic signal at the same AuNRs concentration to explore whether the AuNRs outer layer modified GOx and encapsulated in liposomes would affect its photoacoustic effect. The specific experimental steps include: (1) preparing AuNRs solution and VTGA-ML solution with the same AuNRs concentration; (2) taking about 200 μL of the prepared solution and adding it to the capillary in order from low concentration to high concentration, and using the small animal ultrasound imaging system (Vevo LAZR) for imaging and analysis.

[0088] The results are as follows Figure 8 As shown in a, the PAI of VTGA-ML is similar to that of free AuNRs solution. The results of photoacoustic signal intensity processing show that the photoacoustic imaging intensity of VTGA-ML and AuNRs solution is significantly linearly correlated with the concentration of AuNRs solution ( Figure 8 b). At the same time, in the range of AuNRs solution concentration of 100-500 μg / mL, the photoacoustic signal intensity generated by VTGA-ML is slightly stronger than that of AuNRs solution. The above results prove that VTGA-ML obtained by modifying GOx on the outer layer of AuNRs and encapsulating it in liposomes does not affect the photoacoustic effect.

[0089] Example 10: Performance evaluation of in vivo photoacoustic imaging (PAI) of VTGA-ML

[0090] In order to investigate the PAI performance of VTGA-ML in vivo, female B16F10 tumor-bearing mice were used as model animals to evaluate the PAI ability of VTGA-ML in vivo. Mice were intravenously injected with NS, AuNRs, and VTGA-ML. After administration, the mice were anesthetized at the predetermined time and imaged using a small animal ultrasound imaging system (Vevo LAZR). All samples were performed in triplicate, and the data are expressed as mean±SD.

[0091] The results are as follows Fig. 9 As shown in ab, as VTGA-ML accumulates in tumor tissue, the PA signal intensity gradually increases. At 12h after intravenous injection, the average PA signal of the tumor in the VTGA-ML group was significantly higher than that in the free AuNRs group (p<0.001). These results indicate that VTGA-ML can accumulate in the tumor site through α-MSH-mediated active targeting, and achieve precise tumor localization through PAI-guided tumor imaging.

[0092] Example 11: Investigation of VTGA-ML cytotoxicity in vitro

[0093] The cytotoxicity of different preparations was determined by MTT assay.3 Cells / well) were seeded in 96-well plates and incubated overnight. Fresh medium containing different preparations was added and incubated for 48 h. 2 The cells were treated with near-infrared laser for 5 min. Then, 5 mg / mL MTT reagent (20 μL) was added to each well and incubated for 4 h. Finally, 200 μL DMSO was added to each well after discarding the supernatant, and the absorbance was measured at 570 nm using a microplate reader (BioTek, USA). All samples were performed in triplicate, and the data are expressed as mean ± SD (n = 3).

[0094] A total of nine groups of preparations were set up: (1) blank liposomes + illumination (B+L); (2) free VP, TH-302 + illumination (VT+L); (3) glucose oxidase modified gold nanorods + illumination (GA+L); (4) free VP, TH-302 + glucose oxidase modified gold nanorods + illumination (VT+GA+L); (5) α-MSH modified loaded VP, TH-302 thermosensitive liposomes + illumination (VT-ML+L); (6) α-MSH modified loaded GA thermosensitive liposomes + illumination (GA-ML+L); (7) α-MSH modified loaded VP, TH-302 and GA thermosensitive liposomes (VTGA-ML); (8) loaded VP, TH-302 and GA thermosensitive liposomes + illumination (VTGA-L+L); (9) α-MSH modified loaded VP, TH-302 and GA thermosensitive liposomes + illumination (VTGA-ML+L).

[0095] The results are as follows Fig.10 As shown, the B+L group did not show obvious cytotoxic effects within the set concentration range, proving that the carrier and light have good safety. On B16F10 cells, the cytotoxicity of the VTGA-ML+L group was higher than that of the GA-ML+L group (p<0.001), indicating that the addition of the new drug combination VP and TH-302 can enhance the mild photothermal effect of GA-ML and better kill tumor cells.

[0096] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A liposome, Its characteristics are: The liposomes contain blank liposomes and active substances ivophosphamide TH-302, verteporfin VP and glucose oxidase-modified gold nanorods GA; The mass ratio of the active ingredients ivophosphamide TH-302, verteporfin VP and glucose oxidase-modified gold nanorods GA in the liposome is 10:1:

3.

2. The liposome according to claim 1, Its characteristics are: The preparation method is as follows: liposomes are prepared by a thin film dispersion method, dipalmitoylphosphatidylcholine, cholesterol, ivophosphamide TH-302, verteporfin VP, and distearoylphosphatidylethanolamine-polyethylene glycol 2000-α-melanocyte stimulating hormone (DSPE-PEG2000-α-MSH) are dissolved, and then rotated to form a film, and then the above-mentioned glucose oxidase-modified gold nanorod GA solution is added, and ultrasonic hydration is performed to obtain a stable thermosensitive liposome (VTGA-ML) solution.

3. A liposome as claimed in claim 2, Its characteristics are: The specific prescription is that the concentration of dipalmitoylphosphatidylcholine is 10 mg / mL, the mass ratio of dipalmitoylphosphatidylcholine / cholesterol is 8:1, the mass ratio of iodophosphamide TH-302: dipalmitoylphosphatidylcholine is 1:10, and the hydration temperature is 45°C.

4. A liposome as claimed in claim 1, Its characteristic is that glucose The preparation method of oxidase-modified gold nanorods GA is as follows: (1) Thiol-polyethylene glycol 2000-amino (SH-PEG 2000 -NH 2 ) was modified on the surface of gold nanorods AuNRs by ultrasound and stirring to obtain gold nanorods-polyethylene glycol 2000-amino (AuNR-PEG 2000 -NH 2 ); (2) Under the catalysis of EDC and NHS, glucose oxidase reacts with the carboxyl group of glucose oxidase and the gold nanorod-polyethylene glycol 2000-amino group (AuNR-PEG 2000 -NH 2 ) undergo an amide reaction to connect the amino groups to obtain glucose oxidase-modified gold nanorods GA.

5. Use of the liposome as claimed in claim 1 in preparing photoacoustic imaging drugs.

6. Use of the liposome as claimed in claim 1 in the preparation of mild photothermal therapy drugs.

7. A drug combination, Its characteristics are: The drug combination is ivophosphamide TH-302 and verteporfin VP, and the mass ratio of the two drugs is 10:

1.

8. Use of the drug combination as claimed in claim 7 in the preparation of anti-tumor drugs.